Associated tags: TNF, Patient, Cancer, NK, Natural killer cell, Inflammation, Disease, Pharmaceutical industry, Medical imaging, Research
Locations: MA, BOSTON, NEWPORT BEACH, CA, NORTH AMERICA, PARK AVENUE, AD, FLORIDA, NEW YORK, ADA
Sale,
TNF,
Phase,
DSM-IV codes,
Patient,
MUC4,
CD47,
Pacific Rim,
CTLA4,
LAG3,
Research,
Tumor microenvironment,
Conference,
Downregulation and upregulation,
Disease,
Exercise,
Chemistry,
SRC,
Macrophage,
BOCA,
TIGIT,
Treatment-resistant depression,
Neuroinflammation,
Neoplasm,
Deficit spending,
TME,
Pharmaceutical industry BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.
Key Points:
- BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.
- INB03 cancer platform – two posters were presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
- Financial Results for the First Quarter Ended March 31, 2024:
Net loss attributable to common stockholders for the quarter ended March 31, 2024 was approximately $11.0 million, compared to approximately $6.5 million during the quarter ended March 31, 2023.
- Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.
Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 PM EDT to discuss results for its first quarter ended March 31, 2024 and to provide a corporate update.
Key Points:
- Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc .
- To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
- Please ask for the INmune Bio Fourth Quarter Conference Call when reaching the operator.
- A live audio webcast of the call can be accessed by clicking here or using this link:
The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described below).
Key Points:
- The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described below).
- The offering was priced at-the-market under Nasdaq rules based on the average of the previous 5-days’ closing prices, or $9.84 per share which includes $0.125 per warrant.
- The gross proceeds of this offering are approximately $9.7 million before deducting placement agent fees and expenses.
- The closing of the offering is expected to occur on or about April 29, 2024, subject to the satisfaction of customary closing conditions.
ACE,
Cytokine,
MD,
Cross,
Disease,
Patent,
Patient,
Chemistry,
Serum,
Biomarker,
Temperature,
Pharmaceutical industry The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability.
Key Points:
- The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability.
- The 24-month stability claim is consistent with other pegylated cytokines, such as alpha-interferon, and allows the Company to design a global supply chain using proven and established systems.
- The 24-month stability data confirms that XProTM can mirror these established supply chain strategies.
- The detection of anti-drug antibodies for XProTM in human serum according to the new assay utilizes a novel ACE-AG format.
The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering.
Key Points:
- The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering.
- The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share.
- The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered.
- The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses.
TNF,
MUC4,
Alpha globulin,
Disease,
Macrophage,
CD47,
LAG3,
Breast cancer,
TIGIT,
Poster,
ADCP,
TNBC,
Vaccine Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC). INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin). The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
Key Points:
- The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
- Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03.
- The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate.
- Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.
EEG, which is widely considered a gold standard for objectively measuring brain activity, offers valuable insights into neural connectivity.
Key Points:
- EEG, which is widely considered a gold standard for objectively measuring brain activity, offers valuable insights into neural connectivity.
- Neurological research has consistently shown a progressive decline in alpha band power and frequency in individuals with MCI and Alzheimer's disease.
- Expect to complete enrollment in the Phase I portion of the mCRPC trial by end of Q3 2024 with data in Q4 2024.
- Please ask for the INmune Bio Fourth Quarter Conference Call when reaching an operator.
Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and inflammation company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 28, 2024 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2023 and to provide a corporate update.
Key Points:
- Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc .
- To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
- Please ask for the INmune Bio Fourth Quarter Conference Call when reaching an operator.
- A live audio webcast of the call can be accessed by clicking here or using this link:
Retrieved on:
Wednesday, March 13, 2024
ICST,
ISCT,
International Society,
Disease,
Science,
Career Achievement Award,
Patient,
Knowledge,
Lead,
Gene,
University College London,
GMP,
CGT,
CSO,
Vaccine Boca Raton, Florida, March 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy (ISCT), which the organization considers its highest honor. The award was announced as part of the annual ICST Major Awards announcement. Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
Key Points:
- The award was announced as part of the annual ICST Major Awards announcement.
- Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
- The ISCT is the elite organization in the field of cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief Executive Officer.
- “I am honored to receive this most prestigious award in recognition of my life’s work and wish to thank the members of the ISCT.
Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
Key Points:
- Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
- Patients who received weekly XPro™ treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p
- Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer’s Disease.
- EEG's capability to assess brain function makes these findings particularly noteworthy for INmune Bio’s novel treatment strategy.
